Mark Feinglos
Overview
Explore the profile of Mark Feinglos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bent B, Cho P, Wittmann A, Thacker C, Muppidi S, Snyder M, et al.
BMJ Open Diabetes Res Care
. 2022 Sep;
9(1).
PMID: 36170350
Introduction: Diabetes prevalence continues to grow and there remains a significant diagnostic gap in one-third of the US population that has pre-diabetes. Innovative, practical strategies to improve monitoring of glycemic...
2.
Park T, Bresnahan M, Griggs S, Chen J, Cho A, Gousse Y, et al.
Explor Res Clin Soc Pharm
. 2022 Apr;
2:100022.
PMID: 35481118
Background: The effects of dipeptidyl peptidase-4 inhibitors (DPP4Is) on joint pain have been controversial. Objective: To assess the comparative musculoskeletal (MSk) risk of DPP4Is vs. non-DPP4Is. Methods: This study used...
3.
Bent B, Cho P, Henriquez M, Wittmann A, Thacker C, Feinglos M, et al.
NPJ Digit Med
. 2021 Jun;
4(1):89.
PMID: 34079049
Prediabetes affects one in three people and has a 10% annual conversion rate to type 2 diabetes without lifestyle or medical interventions. Management of glycemic health is essential to prevent...
4.
Merwin R, Moskovich A, Babyak M, Feinglos M, Honeycutt L, Mooney J, et al.
J Eat Disord
. 2021 Jan;
9(1):6.
PMID: 33407910
Background: Eating disorders (EDs) among individuals with type 1 diabetes (T1D) increase the risk of early and severe diabetes-related medical complications and premature death. Conventional eating disorder (ED) treatments have...
5.
Setji T, Feinglos M
Expert Rev Endocrinol Metab
. 2019 Feb;
8(3):229-238.
PMID: 30780810
Glucagon-like peptide-1 receptor agonists have become an important therapeutic option for patients with Type 2 diabetes because of their ability to lower blood glucose and help patients lose weight. There...
6.
Kreider K, Feinglos M
Eur J Intern Med
. 2018 May;
54:e25-e26.
PMID: 29773415
No abstract available.
7.
Merwin R, Moskovich A, Honeycutt L, Lane J, Feinglos M, Surwit R, et al.
Psychosom Med
. 2017 Dec;
80(2):222-229.
PMID: 29206725
Objective: Restricting insulin to lose weight is a significant problem in the clinical management of type 1 diabetes (T1D). Little is known about this behavior or how to effectively intervene....
8.
Luginbuhl K, Schaal J, Umstead B, Mastria E, Li X, Banskota S, et al.
Nat Biomed Eng
. 2017 Oct;
1.
PMID: 29062587
Stimulation of the glucagon-like peptide-1 (GLP1) receptor is a useful treatment strategy for type 2 diabetes because of pleiotropic effects, including the regulation of islet hormones and the induction of...
9.
Luo H, Pan W, Sloan F, Feinglos M, Wu B
Prev Chronic Dis
. 2015 Dec;
12:E211.
PMID: 26632952
Introduction: This study aimed to assess the trends in tooth loss among adults with and without diabetes mellitus in the United States and racial/ethnic disparities in tooth loss patterns, and...
10.
Merwin R, Dmitrieva N, Honeycutt L, Moskovich A, Lane J, Zucker N, et al.
Diabetes Care
. 2015 Sep;
38(11):2025-32.
PMID: 26384389
Objective: Individuals with type 1 diabetes who restrict insulin to control weight are at high risk for diabetes-related complications and premature death. However, little is known about this behavior or...